On the recordFebruary 23, 2021
I will say, for the Johnson & Johnson product, I am very curious to see how that product will be discussed at FDA's Advisory Committee on Friday.
Source
congress.govI will say, for the Johnson & Johnson product, I am very curious to see how that product will be discussed at FDA's Advisory Committee on Friday.
Tillis expresses interest in the FDA's discussion on the Johnson & Johnson vaccine.
Share
More from Thom Tillis